Going off the Gold Standard: Replacing Gel Electrophoresis with Mass Spectrometry
By MCL Education • April 8, 2019
Expiration date: April 8, 2021
Since the late 1960s, gel electrophoresis has been the standard of care for the detection of monoclonal proteins. Mayo Clinic’s high throughput clinical electrophoresis laboratory has stagnated in tests per full-time employee (FTE) as manual, semi-batch runs and paper result tracking are limiting our gel-based detection of monoclonal immunoglobulins (M-proteins). We recently described a MALDI-TOF mass spectrometry method (MASS-FIX) as a plausible replacement for gel-based immunofixation (IFE). However, to use MASS-FIX, a fully validated, automated method meeting current analytical capabilities was required. This webinar will cover the development work, clinical applications, analytical validation, and implementation of a MASS-FIX within the Mayo Clinic Protein Immunology Laboratory.
David Murray, M.D., Ph.D. Assistant Professor of Laboratory Medicine and Pathology Division of Clinical Biochemistry and Immunology Mayo Clinic, Rochester, Minnesota
Upon completion of this activity, participants should be able to:
Demonstrate how immunoglobulin light-chain mass distributions can be used to detect M-proteins.
Illustrate the clinical utility of MASS-FIX through case presentations.
Educate laboratorians on the proper ordering of the MASS-FIX based panels.
This webinar is intended for hematologists, oncologists, and hematopathologists who diagnose and treat patients with multiple myeloma.
The following types of credit are offered for this event: ASCLS P.A.C.E.®
To obtain credit:
Watch the video.
Complete the posttest and evaluation that launches immediately following the video.
Generate and print your certificate(s).
Level of Instruction
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
This post was developed by our Education and Technical Publications Team.